Skip to main content
Contact Us

Manufacturing & Regulatory

Contract & Toll Manufacturing of Pharmaceuticals in Pakistan: DRAP Guidelines, Quality Protocols & Partner Selection

Updated September 2026 8 min read Medically & Technically Reviewed

The pharmaceutical manufacturing sector in Pakistan has evolved into a strategic regional hub for high-volume, cost-effective generic medicine production. For marketing authorization holders, multinational subsidiaries, and healthcare brand owners, outsourcing production through contract or toll manufacturing offers substantial capital efficiency—provided that regulatory compliance under the Drug Regulatory Authority of Pakistan (DRAP) and WHO-GMP standards are rigorously met.

Table of Contents

Key Takeaway for Decision Makers

Selecting a pharmaceutical manufacturing partner in Pakistan requires balancing commercial tolling economics with uncompromised regulatory compliance. Under DRAP rules, both contract giver and contract acceptor bear joint responsibility for product quality, stability documentation, and batch pharmacovigilance.

1. The Contract Manufacturing Landscape in Pakistan

Over the past decade, capital expenditure requirements for dedicated pharmaceutical manufacturing facilities have escalated due to stricter cGMP standards, cleanroom classification demands (ISO 14644 Class A to D), and automated HVAC environmental controls. Rather than tying up tens of millions of dollars in brick-and-mortar facilities, pharmaceutical brand owners increasingly partner with established licensed manufacturers.

Pakistan's pharmaceutical sector comprises more than 750 licensed units, yet fewer than 15% possess multi-dosage WHO-GMP certified infrastructure capable of supporting international-standard contract manufacturing. Star Laboratories (Pvt) Ltd, founded in 1962, operates integrated human and veterinary manufacturing plants in Lahore, delivering contract capabilities across sterile and non-sterile dosage lines.

2. Contract Manufacturing vs. Toll Manufacturing

When structuring a third-party production arrangement, understanding the commercial and operational distinction between contract manufacturing and toll manufacturing is vital:

Aspect Contract Manufacturing (Turnkey) Toll Manufacturing (Tolling)
Raw Material Sourcing Manufacturer sources approved APIs and excipients from qualified vendors. Client (Contract Giver) provides APIs and designated packaging components.
Capital Outlay Client pays per finished batch / unit price with lower operational overhead. Client finances inventory; pays manufacturing fee per unit processed.
Regulatory Registration Manufacturer supports product dossier preparation and DRAP registration filings. Client holds registration rights; manufacturer listed as approved site.
Best Suited For Startups, international importers, and commercial brand expansions. Large pharma corporations managing API procurement supply chains.

3. DRAP Regulatory Requirements & Legal Compliance

Contract manufacturing in Pakistan is governed under the Drugs Act 1976 and the DRAP Act 2012. Under these provisions, any outsourcing agreement must satisfy the following statutory checkpoints:

  • Valid Drug Manufacturing Licence (DML): The contracted facility must possess a current, unencumbered DML covering the specific dosage section (e.g., Cephalosporin Injectable, General Oral Solids, Veterinary Suspensions).
  • Formal Technical & Quality Agreement: A comprehensive legal document defining batch release authority, Quality Assurance (QA) responsibilities, deviation reporting, stability monitoring, and product recall protocols.
  • DRAP Notification / Prior Approval: In accordance with statutory rules, third-party manufacturing arrangements must be notified to and sanctioned by the Central Licensing Board (CLB) or relevant DRAP registration boards.
  • Certificate of Pharmaceutical Product (CoPP): Essential for products intended for export, confirming compliance with WHO-recommended standards.

4. Technology Transfer and Analytical Method Validation

A successful contract manufacturing relationship depends on seamless technology transfer. At Star Laboratories, tech-transfer follows a 4-phase protocol:

  1. 1

    Feasibility & Gap Analysis

    Evaluation of master formula, target release specifications, active ingredient compatibility, and tooling requirements.

  2. 2

    Analytical Method Transfer & Validation

    Cross-validation of HPLC, spectrophotometric, and chemical assay methods between client laboratories and Star Labs QC testing units.

  3. 3

    Pilot & Scale-Up Batch Processing

    Manufacturing pilot batches to verify blending uniformity, compression kinetics, coating parameters, or fill-finish precision.

  4. 4

    Commercial Process Validation & Stability

    Execution of three consecutive commercial validation batches subjected to ICH Zone IVa/IVb accelerated and real-time stability protocols.

5. Key Criteria for Selecting a Manufacturing Partner

When auditing prospective contract facilities in Pakistan, healthcare organizations should verify:

  • Cleanroom Engineering: Validated HVAC differential pressures, HEPA filtration (0.3 micron efficiency), temperature (≤25°C) and relative humidity controls (≤50% for effervescent or moisture-sensitive solids).
  • Water Purification Infrastructure: Reverse Osmosis (RO) and multi-column distillation systems yielding USP-grade Water for Injection (WFI) and purified water.
  • Dedicated Containment Sections: Strict physical separation for beta-lactams, cephalosporins, and veterinary products to completely prevent cross-contamination.
  • Analytical Instrumentation: High-Performance Liquid Chromatography (HPLC), Gas Chromatography, UV/Vis spectrophotometers, and dissolution apparatus running 21 CFR Part 11 compliant software.

Published by Star Laboratories Technical & Regulatory Advisory Board

Star Laboratories (Pvt) Ltd is a WHO-GMP certified manufacturer licensed by DRAP since 1962, producing over 600 human and veterinary formulations across oral solids, liquid orals, parenterals, and topical dosage forms for domestic supply and export to 30+ countries.

6. Frequently Asked Questions (FAQ)

What is the typical lead time for contract manufacturing in Pakistan?

For existing formulations with approved raw materials, commercial batch production typically requires 4 to 6 weeks. For new formulation tech-transfers requiring stability trials and DRAP registration updates, timelines range from 3 to 6 months.

Can international pharmaceutical brands contract manufacture in Pakistan for export?

Yes. International importers and distributors can establish contract manufacturing contracts in Pakistan. Star Laboratories provides complete export documentation, including Certificate of Pharmaceutical Product (CoPP), stability test data, and CTD/ACTD registration dossiers for regulatory submission across Asia, Africa, and the Middle East.

How does Star Laboratories prevent cross-contamination in contract manufacturing?

Star Laboratories enforces cGMP containment protocols with physically segregated production blocks for distinct therapeutic categories (e.g. general human medicines, cephalosporins, veterinary lines), dedicated air-handling units (AHUs) with non-recirculating terminal HEPA filters, and validated clean-in-place (CIP) procedures.

Discuss Your Contract Manufacturing Requirements

Whether you need turnkey generic batch production or dedicated tolling lines for human or veterinary medicines, our technical team is ready to assist.

View Contract Manufacturing Services Request Technical Consultation